Author:
Yu Hengyi,Fang Yinian,Qi Xinxin,Wang Kaifu,Lei Yongfang,Zhang Donglin,Chen Qian,Liu Dong,Ren Xiuhua
Abstract
AbstractChina has became the world’s second largest pharmaceutical market, and the number of her registered clinical trials exceeded 3000 in 2021. Although thousands of healthy volunteers are participating in a large number of clinical trials in this country, there is no report about the characteristics, recognition, attitude of Chinese healthy volunteers and their concerns of clinical trials. A questionnaire survey was designed and given to 324 healthy volunteers participating in clinical trials in Wuhan, China. Four important findings emerged from our data. First, young, single and less educated men constituted the majority of Chinese healthy volunteers. Second, differences between the male and female healthy volunteers were observed. Female healthy volunteers are supposed to face more challenges and pressure in life, be more cautious about the clinical trials and more concerned about their health and feelings than the male. Third, no sociodemographic characteristic was associated with poorly understanding of the protocol research content, which was subjectively evaluated. Fourth, more support from society/family and more positive media reports about the participation of healthy volunteers in clinical trials are badly needed. These findings would help us to get a better understanding of Chinese healthy volunteers as a group for protecting them and promoting drug development.
Funder
National Natural Science Foundation of China
National Major Scientific and Technological Special Project for Significant New Drugs Development
Publisher
Springer Science and Business Media LLC
Reference19 articles.
1. Ouyang, Y. Evolving health-care regulations in China. Lancet Oncol. 18, 714 (2017).
2. Jakovljevic, M. et al. Asian innovation in pharmaceutical and medical device industry-beyond tomorrow. J. Med. Econ. 24, 42–50 (2021).
3. Bao, J. & Hafner, R. Conducting high-quality tuberculosis clinical trials in China: Opportunities and challenges. Int. J. Tuberc. Lung Dis. 21, 1094–1100 (2017).
4. The State Council, The People’s Republic of China. http://www.gov.cn/zhengce/content/2015-08/18/content_10101.htm (2015).
5. Lin, L. et al. Analysis of clinical trials of new drugs in China as of 2019. Drug Discov. Today. 25, 2080–2088 (2020).
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献